PDF Brochure Idiopathic Pulmonary Fibrosis Pipeline Assessment respiratory disease by benbenzhou

VIEWS: 17 PAGES: 5

More Info
									Brochure
More information from http://www.researchandmarkets.com/reports/1268111/




Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market
Forecasts to 2017

Description:    Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017

                Summary

                Our pharmaceutical and healthcare report, “Idiopathic Pulmonary Fibrosis - Pipeline Assessment
                and Market Forecasts to 2017” is an essential source of information and analysis on the global
                idiopathic pulmonary fibrosis market. The report identifies the key trends shaping and driving the
                global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent
                competitive landscape and the emerging players expected to bring significant shift in the market
                positioning of the existing market leaders. Most importantly, the report provides valuable insight on
                the pipeline products within the global idiopathic pulmonary fibrosis sector. This report is built using
                data and information sourced from proprietary databases, primary and secondary research and in
                house analysis by Our team of industry experts.

                The global Idiopathic Pulmonary Fibrosis (IPF) market was valued at $88m in 2009. It is expected
                to increase with a compound annual growth rate (CAGR) of 23% from $88m in 2009 to $462m by
                2017. Earlier, the IPF market was underserved due to a lack of approved products. In October
                2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under
                regulatory review for approval in the US and EU. The expected increase in sales is due to the
                expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and
                Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the
                anticipated approval of Letiaris and Tracleer. Gilead’s Letiaris and Actelion’s Tracleer are the most
                anticipated molecules in the IPF market.

                Scope

                The report provides information on the key driver and challenges of the idiopathic pulmonary
                fibrosis market. Its scope includes:
                - Annualized global idiopathic pulmonary fibrosis market revenues data from 2001 to 2009, forecast
                forward for eight years to 2017.
                - Pipeline analysis data providing a split across the different phases, mechanisms of action being
                developed and emerging trends. Key classes of mechanism of action include enzyme inhibitors,
                protein inhibitors, endothelin A antagonists, combination therapy, TNF alpha antagonists, platelet
                aggregation inhibitors, interferon alpha, interleukin inhibitors, immunosuppresants, growth
                hormone inhibitors, gene therapy, LPA1 receptor antagonists, tumor growth factor inhibitors and
                NK-1 antagonists.
                - Analysis of the current and future market competition in the global idiopathic pulmonary fibrosis
                market. Key market players covered are Gilead Sciences, Actelion Ltd., Amgen Inc., InterMune Inc.
                and Amarillo Biosciences.
                - Insightful review of the key industry drivers, restraints and challenges. Each trend is
                independently researched to provide qualitative analysis of its implications.
                - Key topics covered include strategic competitor assessment, market characterization, unmet
                needs and the implications for the future market associated with idiopathic pulmonary fibrosis
                therapeutics.

                Reasons to buy

                The report will enhance your decision making capability in a rapid and time sensitive manner. It will
                allow you to:
                - Develop and design your in-licensing and out-licensing strategies through a review of pipeline
                products and technologies and by identifying the companies with the most robust pipeline.
                - Develop business strategies by understanding the trends shaping and driving the global idiopathic
                pulmonary fibrosis market.
                - Drive revenues by understanding the key trends, innovative products and technologies, market
            segments and companies likely to impact the global idiopathic pulmonary fibrosis market in future.
            - Formulate effective sales and marketing strategies by understanding the competitive landscape
            and by analyzing the performance of various competitors.
            - Identify emerging players with potentially strong product portfolios and create effective counter-
            strategies to gain the competitive advantage.
            - Organize your sales and marketing efforts by identifying the market categories and segments that
            present maximum opportunities for consolidations, investments and strategic partnerships.
            - What’s the next big thing in the global idiopathic pulmonary fibrosis market landscape? - Identify,
            understand and capitalize.



Contents:   1 Table of contents
            1.1 List of Tables
            1.2 List of Figures
            2 Global Idiopathic Pulmonary Fibrosis Market: Market Characterization
            2.1 Overview
            2.2 Idiopathic Pulmonary Fibrosis Market Size
            2.3 Idiopathic Pulmonary Fibrosis Market Forecast and CAGR
            2.4 Drivers and Barriers for Idiopathic Pulmonary Fibrosis Market
            2.4.1 Drivers for Idiopathic Pulmonary Fibrosis Market
            2.4.2 Barriers for Idiopathic Pulmonary Fibrosis Market
            2.5 Opportunity and Unmet Need
            2.6 Key Takeaway
            3 Idiopathic Pulmonary Fibrosis Market: Competitive Assessment
            3.1 Overview
            3.2 Strategic Competitor Assessment
            3.3 Profiles of the Major Therapeutic Class in Idiopathic Pulmonary Fibrosis
            3.3.1 Overview
            3.3.2 Immunosuppresants
            3.3.3 Anti-inflammatory Drugs
            3.3.4 Antifibrotics
            3.4 Key Takeaway
            4 Idiopathic Pulmonary Fibrosis Market: Pipeline Assessment
            4.1 Overview
            4.2 Strategic Pipeline Assessment
            4.2.1 Technology Trends Analytic Framework
            4.3 Idiopathic Pulmonary Fibrosis Therapeutics - Promising Drugs under Clinical Development
            4.4 Molecule Profile for Promising Drugs for Idiopathic Pulmonary Fibrosis under Clinical
            Development
            4.4.1 Letairis (ambrisentan)
            4.4.2 Tracleer (bosentan)
            4.4.3 Enbrel (etanercept)
            4.4.4 Veldona (Oral interferon alfa)
            4.5 Idiopathic Pulmonary Fibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action
            4.6 Idiopathic Pulmonary Fibrosis Pipeline - Pipeline by Clinical Phases of Development
            4.6.1 Idiopathic Pulmonary Fibrosis Therapeutics - Phase III Clinical Pipeline
            4.6.2 Idiopathic Pulmonary Fibrosis Therapeutics - Phase II Clinical Pipeline
            4.6.3 Idiopathic Pulmonary Fibrosis Therapeutics - Phase I Clinical Pipeline
            4.6.4 Idiopathic Pulmonary Fibrosis Therapeutics - Preclinical Pipeline
            4.7 Discontinued / Suspended Drug for Idiopathic Pulmonary Fibrosis
            4.8 Key Takeaway
            5 Idiopathic Pulmonary Fibrosis : Implications for Future Market Competition
            6 Idiopathic Pulmonary Fibrosis Market: Future Players in the Idiopathic Pulmonary Fibrosis Market
            6.1 Introduction
            6.2 Gilead Sciences, Inc., California
            6.2.1 Overview
            6.2.2 Respiratory Disease Portfolio
            6.2.3 Idiopathic Pulmonary Fibrosis Product Portfolio
            6.3 Actelion Ltd.
            6.3.1 Overview
            6.3.2 Respiratory Disease Portfolio
            6.3.3 Idiopathic Pulmonary Fibrosis Product Portfolio
            6.4 Amgen Inc.
            6.4.1 Overview
            6.4.2 Respiratory Disease Portfolio
            6.4.3 Idiopathic Pulmonary Fibrosis Product Portfolio
            6.5 InterMune, Inc.
            6.5.1 Overview
            6.5.2 Respiratory Disease Portfolio
            6.6 Amarillo Biosciences
            6.6.1 Overview
            6.6.2 Respiratory Disease Portfolio
            6.6.3 Idiopathic Pulmonary Fibrosis Product Portfolio
            7 Idiopathic Pulmonary Fibrosis Market: Appendix
            7.1 Market Definitions
            7.2 Abbreviations
            7.3 Research Methodology
            7.3.1 Coverage
            7.3.2 Secondary Research
            7.3.3 Forecasting
            7.3.4 Primary Research
            7.3.5 Expert Panel validation
            7.4 Contact Us
            7.5 Disclaimer
            7.6 Sources



Ordering:   Order Online - http://www.researchandmarkets.com/reports/1268111/

            Order by Fax - using the form below

            Order by Post - print the order form below and sent to

                          Research and Markets,
                          Guinness Centre,
                          Taylors Lane,
                          Dublin 8,
                          Ireland.
                                                           Page 1 of 2

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-
1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.


               Product Name:           Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to
                                       2017
               Web Address:            http://www.researchandmarkets.com/reports/1268111/
               Office Code:            OC8HMIMTOQNTT

Product Formats
Please select the product formats and quantity you require:


                                   Quantity

               Electronic:               EURO €1,518.00

               Electronic:               EURO €3,035.00

               Electronic:               EURO €4,553.00




Contact Information
Please enter all the information below in BLOCK CAPITALS


      Title:                  Mr              Mrs           Dr           Miss                 Ms     Prof

      First Name:                                                  Last Name:

      Email Address: *

      Job Title:

      Organisation:

      Address:

      City:

      Postal / Zip Code:

      Country:

      Phone Number:

      Fax Number:

     * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
                                                              Page 2 of 2

Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

          Pay by credit card:                     American Express

                                                  Diners Club

                                                  Master Card

                                                  Visa
                                           Cardholder's Name

                                           Cardholder's Signature

                                           Expiry Date

                                           Card Number

                                           CVV Number

                                           Issue Date
                                           (for Diners Club only)




          Pay by check:                    Please post the check, accompanied by this form, to:

                                           Research and Markets,
                                           Guinness Center,
                                           Taylors Lane,
                                           Dublin 8,
                                           Ireland.


                                           Please transfer funds to:
          Pay by wire transfer:
                                           Account number                   833 130 83
                                           Sort code                        98-53-30
                                           Swift code                       ULSBIE2D
                                           IBAN number                      IE78ULSB98533083313083
                                           Bank Address                 Ulster Bank,
                                                                        27-35 Main Street,
                                                                        Blackrock,
                                                                        Co. Dublin,
                                                                        Ireland.


     If you have a Marketing Code please enter it below:


           Marketing Code:


      Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
     http://www.researchandmarkets.com/info/terms.asp



                                              Please fax this form to:
                                  (646) 607-1907 or (646) 964-6609 - From USA
                          +353 1 481 1716 or +353 1 653 1571 - From Rest of World

								
To top